MARKET

BBOT

BBOT

BridgeBio Oncology Therapeutics, Inc
NASDAQ
7.69
+0.25
+3.36%
Closed 17:39 06/25 EDT
OPEN
7.45
PREV CLOSE
7.44
HIGH
8.02
LOW
7.39
VOLUME
475.21K
TURNOVER
0
52 WEEK HIGH
14.87
52 WEEK LOW
7.00
MARKET CAP
616.02M
P/E (TTM)
38.51
1D
5D
1M
3M
1Y
5Y
1D
BridgeBio Oncology Holders Elect Directors, Ratify Auditor
TipRanks · 3d ago
BridgeBio Oncology Therapeutics shareholders elect Lebowitz, McCormick to board
PUBT · 3d ago
BridgeBio Oncology Price Target Announced at $22.00/Share by Oppenheimer
Dow Jones · 3d ago
Oppenheimer Assumes BridgeBio Oncology at Outperform, Announces Price Target of $22
Benzinga · 3d ago
BridgeBio Oncology assumed with an Outperform at Oppenheimer
TipRanks · 4d ago
Weekly Report: what happened at BBOT last week (0615-0619)?
Weekly Report · 4d ago
Weekly Report: what happened at BBOT last week (0608-0612)?
Weekly Report · 06/15 10:34
John Newman Reiterates Buy on BridgeBio Oncology Therapeutics, Sets $23 Price Target on Differentiated KRAS G12C Profile
TipRanks · 06/08 12:35
More
About BBOT
Bridgebio Oncology Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on advancing the pipeline of novel small molecule therapeutics targeting RAS and PI3Ka malignancies. Its pipeline of RAS-targeted oncology drug candidates includes BBO-8520, BBO-10203, and BBO-11818. BBO-8520 (NCT06343402) is a direct inhibitor of KRASG12C in both the ON and OFF states that is being evaluated both as monotherapy and in combination with pembrolizumab in the Phase 1 ONKORAS-101 trial for patients with KRASG12C mutant non-small cell lung cancer. BBO-10203 (NCT06625775) is an orally bioavailable small molecule that selectively and specifically blocks the physical interaction between RAS and PI3Ka, resulting in the inhibition of RAS-driven PI3Ka-AKT signaling in tumors without the risk of hyperglycemia. BBO-11818 (NCT06917079) is a panKRAS inhibitor targeting mutant KRAS in both the ON and OFF states with strong potency against KRASG12D and KRASG12V mutants.

Webull offers BridgeBio Oncology Therapeutics Inc stock information, including NASDAQ: BBOT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BBOT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading BBOT stock methods without spending real money on the virtual paper trading platform.